{"id":"https://openalex.org/W4282932645","doi":"https://doi.org/10.1158/1538-7445.am2022-654","title":"Abstract 654: CD28 shedding is a novel resistance mechanism to anti PD-1 therapy","display_name":"Abstract 654: CD28 shedding is a novel resistance mechanism to anti PD-1 therapy","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282932645","doi":"https://doi.org/10.1158/1538-7445.am2022-654"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-654","doi":"https://doi.org/10.1158/1538-7445.am2022-654","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-654","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062499278","display_name":"Motti Hakim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Motti Hakim","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075829640","display_name":"Anna Fridman Dror","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Fridman Dror","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032130180","display_name":"Tal Shahar Gabay","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tal Shahar Gabay","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050986548","display_name":"Dror Alishekevitz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dror Alishekevitz","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036750353","display_name":"Edna Meilin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edna Meilin","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002418042","display_name":"Ilana Mandel","orcid":"https://orcid.org/0000-0002-4488-5408","observed_orcids":["https://orcid.org/0000-0002-4488-5408"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ilana Mandel","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005327041","display_name":"Yair Sapir","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yair Sapir","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001233858","display_name":"Avidor Shulman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Avidor Shulman","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018689969","display_name":"Tehila Ben Moshe","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tehila Ben Moshe","raw_affiliation_strings":["1Biond Biologics, Misgav, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Biond Biologics, Misgav, Israel","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"654","last_page":"654"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-resistance","display_name":"anti-PD-1 resistance","score":0.8989999890327454},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8930000066757202},{"id":"https://openalex.org/keywords/mmp-2","display_name":"MMP-2","score":0.7459999918937683},{"id":"https://openalex.org/keywords/mmp-13","display_name":"MMP-13","score":1.0},{"id":"https://openalex.org/keywords/nanobodies","display_name":"nanobodies","score":0.6949999928474426},{"id":"https://openalex.org/keywords/tumor-infiltrating-t-cells","display_name":"tumor-infiltrating T cells","score":0.7559999823570251},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.4740000069141388},{"id":"https://openalex.org/keywords/recurrence","display_name":"recurrence","score":0.5450000166893005},{"id":"https://openalex.org/keywords/fc-fusion","display_name":"Fc fusion","score":0.5180000066757202},{"id":"https://openalex.org/keywords/affinity-maturation","display_name":"affinity maturation","score":0.5860000252723694}],"concepts":[{"id":"https://openalex.org/C148125776","wikidata":"https://www.wikidata.org/wiki/Q1622348","display_name":"CD28","level":4,"score":0.7863914370536804},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.6820058226585388},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5081777572631836},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.48795193433761597},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4850453734397888},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42903101444244385},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.42041927576065063},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.387837290763855},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3822970390319824},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3817526698112488},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.34793317317962646},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.34617966413497925},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3370019197463989},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33531898260116577},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.32370489835739136},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1633351445198059},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-654","doi":"https://doi.org/10.1158/1538-7445.am2022-654","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-654","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4404064327","https://openalex.org/W3083675862","https://openalex.org/W1915043848","https://openalex.org/W2901691024","https://openalex.org/W4408905622","https://openalex.org/W2751228536","https://openalex.org/W2884332748","https://openalex.org/W4392545129","https://openalex.org/W4405320559","https://openalex.org/W2592666036"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Resistance":[2],"mechanisms":[3],"to":[4,68,139,166,180,209,249,307,322,396],"anti-PD1":[5,15,52,167,323],"therapy":[6,16,231,251,399],"remain":[7],"poorly":[8],"understood.":[9],"Studies":[10],"have":[11,24],"implicated":[12],"that":[13,27,44,59,97,276],"efficient":[14],"relies":[17],"specifically":[18],"on":[19,87,212],"intact":[20],"CD28/B7":[21],"signaling.":[22],"We":[23,311],"previously":[25],"shown":[26],"membranal":[28],"CD28":[29,46,103,107,142,150,188,204,282,330,389],"is":[30,62,272,391],"actively":[31],"shed":[32],"by":[33,74,143,173,303,344],"MMP-2":[34],"and":[35,43,78,100,114,134,145,156,185,196,284,340],"MMP-13":[36],"upon":[37],"T":[38,121,214],"cell":[39],"stimulation":[40],"in":[41,71,109,115,220,255,335,347],"humans,":[42],"soluble":[45,243],"can":[47,98,277],"counteract":[48],"the":[49,91,116,181,221,296,299,305,314,326,329,336,359,404],"efficacy":[50,165],"of":[51,85,93,111,119,187,224,235,242,298,316,328,338,361,403],"blocking":[53,168,186],"antibodies":[54],"in-vitro.":[55],"Here":[56],"we":[57,268],"describe":[58],"CD28-shedding":[60,86,160,182,256],"process":[61,333],"a":[63,126,175,199,317,354,392],"potential":[64,318],"novel":[65,265,319,363,393],"resistance":[66,320,394],"mechanism":[67,321,395],"PD-1":[69,88,398],"therapies":[70],"cancer":[72,112,339],"patients,":[73],"using":[75,125],"several":[76],"ex-vivo":[77,138],"in-vivo":[79],"methodologies.":[80],"The":[81,190],"prominent":[82],"unfavorable":[83],"effect":[84],"blockade":[89,324],"prompted":[90],"generation":[92],"BND-67,":[94,270,353],"an":[95,233,273,291],"agent":[96,300],"selectively":[99],"efficiently":[101],"block":[102,281],"shedding.":[104,189],"Methods:":[105],"Soluble":[106],"detection":[108],"plasma":[110,225,240],"patients":[113,228],"culture":[117],"media":[118],"stimulated":[120],"cells":[122,215],"was":[123,171,193,207,301,341],"achieved":[124],"proprietary":[127],"in-house":[128],"ELISA.":[129],"Cancer":[130,408,419],"patient":[131],"processed":[132],"tumors":[133],"PBMC":[135],"were":[136,162,252],"used":[137],"identify":[140],"membrane/soluble":[141],"ELISA":[144],"flow-cytometry.":[146],"MC-38":[147],"challenged":[148],"human":[149,308],"transgenic":[151,348],"mice":[152,158,258],"(CD28-shedding":[153],"permissive":[154,257],"model),":[155],"WT":[157],"(non-permissive":[159],"model)":[161],"compared":[163],"for":[164,178,294,358,407],"antibody.":[169],"BND-67":[170],"isolated":[172],"screening":[174],"VHH":[176,275,306],"library":[177],"binding":[179],"prone":[183],"region":[184],"lead":[191],"clone":[192],"further":[194,342],"affinity-matured":[195,274],"reformatted":[197],"into":[198],"half-life":[200,297],"extended":[201],"construct.":[202],"Results:":[203],"receptor":[205],"density":[206],"found":[208],"be":[210],"lower":[211],"tumor-resident":[213],"then":[216],"their":[217],"matched":[218],"counterparts":[219],"periphery.":[222],"Evaluation":[223],"samples":[226],"from":[227,247],"undergoing":[229],"anti-PD-1":[230,250],"demonstrated":[232],"association":[234],"diseases":[236],"relapse":[237],"with":[238],"elevated":[239],"levels":[241],"CD28.":[244],"Correspondingly,":[245],"relapses":[246],"response":[248],"significantly":[253],"higher":[254],"vs":[259],"non-permissive":[260],"mice.":[261,349],"To":[262],"overcome":[263],"this":[264,362],"regulatory":[266,364],"mechanism,":[267],"generated":[269,352],"which":[271],"effectively":[278],"bind":[279],"CD28,":[280],"shedding":[283,327,390],"has":[285,351],"no":[286],"agonistic":[287],"activity.":[288],"In":[289],"addition,":[290],"optimal":[292],"approach":[293],"increasing":[295],"identified":[302],"fusing":[304],"Fc.":[309],"Conclusions:":[310],"report":[312],"here":[313],"discovery":[315],"involving":[325],"receptor.":[331],"This":[332],"occurs":[334],"setting":[337],"reinforced":[343],"results":[345],"observed":[346],"Biond":[350],"therapeutic":[355],"drug":[356],"candidate":[357],"inhibition":[360],"mechanism.":[365],"Citation":[366],"Format:":[367],"Motti":[368],"Hakim,":[369],"Anna":[370],"Fridman":[371],"Dror,":[372],"Tal":[373],"Shahar":[374],"Gabay,":[375],"Dror":[376],"Alishekevitz,":[377],"Edna":[378],"Meilin,":[379],"Ilana":[380],"Mandel,":[381],"Yair":[382],"Sapir,":[383],"Avidor":[384],"Shulman,":[385],"Tehila":[386],"Ben":[387],"Moshe.":[388],"anti":[397],"[abstract].":[400],"In:":[401],"Proceedings":[402],"American":[405],"Association":[406],"Research":[409],"Annual":[410],"Meeting":[411],"2022;":[412],"2022":[413],"Apr":[414],"8-13.":[415],"Philadelphia":[416],"(PA):":[417],"AACR;":[418],"Res":[420],"2022;82(12_Suppl):Abstract":[421],"nr":[422],"654.":[423]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-09-23T05:00:35.095934","created_date":"2022-06-16T00:00:00"}